{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T07:00:57Z","timestamp":1788850857941,"version":"build-2803163510"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Teva Branded Pharmaceutical Products R&D LLC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40263-025-01197-1","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T19:05:50Z","timestamp":1753815950000},"page":"1139-1156","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety Outcomes with the Long-Acting Subcutaneous Antipsychotic TV-46000 in Schizophrenia: A Post Hoc Analysis of Behavioral, Neuromotor, Endocrine, and Cardiometabolic Outcomes from Two Phase 3 Studies"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7254-5646","authenticated-orcid":false,"given":"Christoph U.","family":"Correll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Knebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eran","family":"Harary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Eshet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orna","family":"Tohami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Suett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nir","family":"Sharon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelli R.","family":"Franzenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,29]]},"reference":[{"issue":"9","key":"1197_CR1","first-page":"638","volume":"39","author":"KR Patel","year":"2014","unstructured":"Patel KR, Cherian J, Gohil K, Atkinson D. Schizophrenia: overview and treatment options. P T. 2014;39(9):638\u201345.","journal-title":"P T"},{"issue":"3","key":"1197_CR2","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1001\/archpsyc.56.3.241","volume":"56","author":"D Robinson","year":"1999","unstructured":"Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56(3):241\u20137. https:\/\/doi.org\/10.1001\/archpsyc.56.3.241.","journal-title":"Arch Gen Psychiatry"},{"issue":"1\u20133","key":"1197_CR3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.schres.2011.08.024","volume":"133","author":"R Bod\u00e9n","year":"2011","unstructured":"Bod\u00e9n R, Brandt L, Kieler H, Andersen M, Reutfors J. Early non-adherence to medication and other risk factors for rehospitalization in schizophrenia and schizoaffective disorder. Schizophr Res. 2011;133(1\u20133):36\u201341. https:\/\/doi.org\/10.1016\/j.schres.2011.08.024.","journal-title":"Schizophr Res"},{"issue":"3","key":"1197_CR4","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/wps.20060","volume":"12","author":"JM Kane","year":"2013","unstructured":"Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry. 2013;12(3):216\u201326. https:\/\/doi.org\/10.1002\/wps.20060.","journal-title":"World Psychiatry"},{"issue":"5","key":"1197_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S2215-0366(21)00039-0","volume":"8","author":"T Kishimoto","year":"2021","unstructured":"Kishimoto T, Hagi K, Kurokawa S, Kane JM, Correll CU. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry. 2021;8(5):387\u2013404. https:\/\/doi.org\/10.1016\/S2215-0366(21)00039-0.","journal-title":"Lancet Psychiatry"},{"key":"1197_CR6","doi-asserted-by":"publisher","first-page":"619","DOI":"10.2147\/PPA.S127623","volume":"11","author":"D Pilon","year":"2017","unstructured":"Pilon D, Joshi K, Tandon N, Lafeuille MH, Kamstra RL, Emond B, et al. Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic. Patient Prefer Adherence. 2017;11:619\u201329. https:\/\/doi.org\/10.2147\/PPA.S127623.","journal-title":"Patient Prefer Adherence"},{"issue":"8","key":"1197_CR7","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1001\/jamapsychiatry.2015.0270","volume":"72","author":"KL Subotnik","year":"2015","unstructured":"Subotnik KL, Casaus LR, Ventura J, Luo JS, Hellemann GS, Gretchen-Doorly D, et al. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia: a randomized clinical trial. JAMA Psychiat. 2015;72(8):822\u20139. https:\/\/doi.org\/10.1001\/jamapsychiatry.2015.0270.","journal-title":"JAMA Psychiat"},{"issue":"7","key":"1197_CR8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.24163","volume":"5","author":"Y Wei","year":"2022","unstructured":"Wei Y, Yan VKC, Kang W, Wong ICK, Castle DJ, Gao L, et al. Association of long-acting injectable antipsychotics and oral antipsychotics with disease relapse, health care use, and adverse events among people with schizophrenia. JAMA Netw Open. 2022;5(7): e2224163. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.24163.","journal-title":"JAMA Netw Open"},{"issue":"2\u20133","key":"1197_CR9","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.schres.2016.07.018","volume":"176","author":"F Misawa","year":"2016","unstructured":"Misawa F, Kishimoto T, Hagi K, Kane JM, Correll CU. Safety and tolerability of long-acting injectable versus oral antipsychotics: a meta-analysis of randomized controlled studies comparing the same antipsychotics. Schizophr Res. 2016;176(2\u20133):220\u201330. https:\/\/doi.org\/10.1016\/j.schres.2016.07.018.","journal-title":"Schizophr Res"},{"issue":"6","key":"1197_CR10","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1093\/schbul\/sbab063","volume":"47","author":"JM Rubio","year":"2021","unstructured":"Rubio JM, Taipale H, Tanskanen A, Correll CU, Kane JM, Tiihonen J. Long-term continuity of antipsychotic treatment for schizophrenia: a nationwide study. Schizophr Bull. 2021;47(6):1611\u201320. https:\/\/doi.org\/10.1093\/schbul\/sbab063.","journal-title":"Schizophr Bull"},{"issue":"4","key":"1197_CR11","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/eip.12868","volume":"14","author":"B Brown","year":"2020","unstructured":"Brown B, Turkoz I, Mancevski B, Mathews M. Evaluation of paliperidone palmitate long-acting injectable antipsychotic therapy as an early treatment option in patients with schizophrenia. Early Interv Psychiatry. 2020;14(4):428\u201338. https:\/\/doi.org\/10.1111\/eip.12868.","journal-title":"Early Interv Psychiatry"},{"issue":"3","key":"1197_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2658","volume":"33","author":"P Girardi","year":"2018","unstructured":"Girardi P, Del Casale A, Rapinesi C, Kotzalidis GD, Splendori F, Verzura C, et al. Predictive factors of overall functioning improvement in patients with chronic schizophrenia and schizoaffective disorder treated with paliperidone palmitate and aripiprazole monohydrate. Hum Psychopharmacol. 2018;33(3): e2658. https:\/\/doi.org\/10.1002\/hup.2658.","journal-title":"Hum Psychopharmacol"},{"issue":"8","key":"1197_CR13","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1080\/14656566.2016.1174692","volume":"17","author":"L Hargarter","year":"2016","unstructured":"Hargarter L, Bergmans P, Cherubin P, Keim S, Conca A, Serrano-Blanco A, et al. Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia. Expert Opin Pharmacother. 2016;17(8):1043\u201353. https:\/\/doi.org\/10.1080\/14656566.2016.1174692.","journal-title":"Expert Opin Pharmacother"},{"issue":"1\u20133","key":"1197_CR14","first-page":"36","volume":"17","author":"T Ohnishi","year":"2020","unstructured":"Ohnishi T, Kobayashi H, Yamaoka T, Toma T, Imai K, Wakamatsu A, et al. The effects of paliperidone palmitate 1 month on the employment status and social functioning of patients with schizophrenia. Innov Clin Neurosci. 2020;17(1\u20133):36\u201344.","journal-title":"Innov Clin Neurosci."},{"issue":"1","key":"1197_CR15","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41537-019-0091-y","volume":"6","author":"L Phahladira","year":"2020","unstructured":"Phahladira L, Luckhoff HK, Asmal L, Kilian S, Scheffler F, Plessis SD, et al. Early recovery in the first 24 months of treatment in first-episode schizophrenia-spectrum disorders. NPJ Schizophr. 2020;6(1):2. https:\/\/doi.org\/10.1038\/s41537-019-0091-y.","journal-title":"NPJ Schizophr"},{"key":"1197_CR16","doi-asserted-by":"publisher","first-page":"204512532412570","DOI":"10.1177\/20451253241257062","volume":"14","author":"G Vita","year":"2024","unstructured":"Vita G, Tavella A, Ostuzzi G, Tedeschi F, De Prisco M, Segarra R, et al. Efficacy and safety of long-acting injectable versus oral antipsychotics in the treatment of patients with early-phase schizophrenia-spectrum disorders: a systematic review and meta-analysis. Ther Adv Psychopharmacol. 2024;14:20451253241257064. https:\/\/doi.org\/10.1177\/20451253241257062.","journal-title":"Ther Adv Psychopharmacol."},{"key":"1197_CR17","unstructured":"Uzedy\u2122 (risperidone) extended-release injectable suspension [prescribing information]. Parsippany: Teva Neuroscience, Inc.; 2024."},{"issue":"12","key":"1197_CR18","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/S2215-0366(23)00288-2","volume":"10","author":"JM Kane","year":"2023","unstructured":"Kane JM, Harary E, Eshet R, Tohami O, Weiser M, Leucht S, et al. Efficacy and safety of TV-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the USA and Bulgaria. Lancet Psychiatry. 2023;10(12):934\u201343. https:\/\/doi.org\/10.1016\/S2215-0366(23)00288-2.","journal-title":"Lancet Psychiatry"},{"issue":"8","key":"1197_CR19","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40263-024-01102-2","volume":"38","author":"JM Kane","year":"2024","unstructured":"Kane JM, Eshet R, Harary E, Tohami O, Elgart A, Knebel H, et al. A long-term safety and tolerability study of TV-46000 for subcutaneous use in adult and adolescent patients with schizophrenia: a phase 3, randomized, double-blinded clinical trial. CNS Drugs. 2024;38(8):625\u201336. https:\/\/doi.org\/10.1007\/s40263-024-01102-2.","journal-title":"CNS Drugs"},{"issue":"3","key":"1197_CR20","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/wps.20567","volume":"17","author":"TS Stroup","year":"2018","unstructured":"Stroup TS, Gray N. Management of common adverse effects of antipsychotic medications. World Psychiatry. 2018;17(3):341\u201356. https:\/\/doi.org\/10.1002\/wps.20567.","journal-title":"World Psychiatry"},{"issue":"11","key":"1197_CR21","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/S2215-0366(23)00262-6","volume":"10","author":"T Pillinger","year":"2023","unstructured":"Pillinger T, Howes OD, Correll CU, Leucht S, Huhn M, Schneider-Thoma J, et al. Antidepressant and antipsychotic side-effects and personalised prescribing: a systematic review and digital tool development. Lancet Psychiatry. 2023;10(11):860\u201376. https:\/\/doi.org\/10.1016\/S2215-0366(23)00262-6.","journal-title":"Lancet Psychiatry"},{"issue":"7","key":"1197_CR22","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1177\/0269881107078281","volume":"21","author":"C Bushe","year":"2007","unstructured":"Bushe C, Shaw M. Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. J Psychopharmacol. 2007;21(7):768\u201373. https:\/\/doi.org\/10.1177\/0269881107078281.","journal-title":"J Psychopharmacol"},{"key":"1197_CR23","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/502697","volume":"2013","author":"SI Bargiota","year":"2013","unstructured":"Bargiota SI, Bonotis KS, Messinis IE, Angelopoulos NV. The effects of antipsychotics on prolactin levels and women\u2019s menstruation. Schizophr Res Treat. 2013;2013: 502697. https:\/\/doi.org\/10.1155\/2013\/502697.","journal-title":"Schizophr Res Treat"},{"issue":"3","key":"1197_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2827","volume":"37","author":"EH Karslioglu","year":"2022","unstructured":"Karslioglu EH, Kolcu Z, Karslioglu NI, Caykoylu A. Prospective analysis of serum prolactin levels, clinical symptomatology and sexual functions in patients with schizophrenia switched to paliperidone palmitate 3-monthly from paliperidone palmitate 1-monthly: preliminary findings of the first 3 months. Hum Psychopharmacol. 2022;37(3): e2827. https:\/\/doi.org\/10.1002\/hup.2827.","journal-title":"Hum Psychopharmacol"},{"key":"1197_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2021.114030","volume":"302","author":"DL Kelly","year":"2021","unstructured":"Kelly DL, Claxton A, Bidollari I, Du Y. Analysis of prolactin and sexual side effects in patients with schizophrenia who switched from paliperidone palmitate to aripiprazole lauroxil. Psychiatry Res. 2021;302: 114030. https:\/\/doi.org\/10.1016\/j.psychres.2021.114030.","journal-title":"Psychiatry Res"},{"issue":"1","key":"1197_CR26","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1097\/YIC.0b013e32835ba832","volume":"28","author":"I Montalvo","year":"2013","unstructured":"Montalvo I, Ortega L, Lopez X, Sole M, Monseny R, Franch J, et al. Changes in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitate. Int Clin Psychopharmacol. 2013;28(1):46\u20139. https:\/\/doi.org\/10.1097\/YIC.0b013e32835ba832.","journal-title":"Int Clin Psychopharmacol"},{"issue":"5\u20136","key":"1197_CR27","first-page":"28","volume":"13","author":"M Nakamura","year":"2016","unstructured":"Nakamura M, Nagamine T, Sato G, Besho K. Prolactin levels after switching to paliperidone palmitate in patients with schizophrenia. Innov Clin Neurosci. 2016;13(5\u20136):28\u201330.","journal-title":"Innov Clin Neurosci."},{"issue":"20","key":"1197_CR28","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","volume":"64","author":"PM Haddad","year":"2004","unstructured":"Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004;64(20):2291\u2013314. https:\/\/doi.org\/10.2165\/00003495-200464200-00003.","journal-title":"Drugs"},{"issue":"Suppl 1","key":"1197_CR29","first-page":"32","volume":"69","author":"DC Henderson","year":"2008","unstructured":"Henderson DC, Doraiswamy PM. Prolactin-related and metabolic adverse effects of atypical antipsychotic agents. J Clin Psychiatry. 2008;69(Suppl 1):32\u201344.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"1197_CR30","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.23f14790","volume":"84","author":"C Andrade","year":"2023","unstructured":"Andrade C. Prolactin-raising and prolactin-sparing antipsychotic drugs and the risk of fracture and fragility fracture in patients with schizophrenia, dementia, and other disorders. J Clin Psychiatry. 2023;84(1): 23f14790. https:\/\/doi.org\/10.4088\/JCP.23f14790.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"1197_CR31","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1177\/10398562231158925","volume":"31","author":"JD Hope","year":"2023","unstructured":"Hope JD, Keks NA, Copolov DL. Association between long-term use of prolactin-elevating antipsychotics in women and the risk of breast cancer: what are the clinical implications? Australas Psychiatry. 2023;31(2):205\u20138. https:\/\/doi.org\/10.1177\/10398562231158925.","journal-title":"Australas Psychiatry"},{"issue":"3","key":"1197_CR32","doi-asserted-by":"publisher","first-page":"361","DOI":"10.4088\/jcp.v68n0302","volume":"68","author":"OD Howes","year":"2007","unstructured":"Howes OD, Wheeler MJ, Pilowsky LS, Landau S, Murray RM, Smith S. Sexual function and gonadal hormones in patients taking antipsychotic treatment for schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2007;68(3):361\u20137. https:\/\/doi.org\/10.4088\/jcp.v68n0302.","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"1197_CR33","doi-asserted-by":"publisher","first-page":"769","DOI":"10.9758\/cpn.23.1057","volume":"21","author":"S Kim","year":"2023","unstructured":"Kim S, Jeong JH, Um YH, Kim TW, Seo HJ, Hong SC. Prolactin level changes according to atypical antipsychotics use: a study based on clinical data warehouse. Clin Psychopharmacol Neurosci. 2023;21(4):769\u201377. https:\/\/doi.org\/10.9758\/cpn.23.1057.","journal-title":"Clin Psychopharmacol Neurosci."},{"key":"1197_CR34","doi-asserted-by":"publisher","unstructured":"Citrome L, Suett M, Franzenburg KR, Eshet R, Elgart A, 3rd DG, et al. TV-46000, a long-acting subcutaneous risperidone injectable, demonstrated improved patient-centered outcomes in patients with schizophrenia. Neuropsychiatr Dis Treat. 2024;20:1901\u201317. https:\/\/doi.org\/10.2147\/NDT.S459104","DOI":"10.2147\/NDT.S459104"},{"issue":"2","key":"1197_CR35","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1093\/schbul\/sbu067","volume":"41","author":"PF Buckley","year":"2015","unstructured":"Buckley PF, Schooler NR, Goff DC, Hsiao J, Kopelowicz A, Lauriello J, et al. Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE study. Schizophr Bull. 2015;41(2):449\u201359. https:\/\/doi.org\/10.1093\/schbul\/sbu067.","journal-title":"Schizophr Bull"},{"issue":"3","key":"1197_CR36","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m13207","volume":"81","author":"PJ Weiden","year":"2020","unstructured":"Weiden PJ, Claxton A, Kunovac J, Walling DP, Du Y, Yao B, et al. Efficacy and safety of a 2-month formulation of aripiprazole lauroxil with 1-day initiation in patients hospitalized for acute schizophrenia transitioned to outpatient care: phase 3, randomized, double-blind, active-control ALPINE study. J Clin Psychiatry. 2020;81(3): 19m13207. https:\/\/doi.org\/10.4088\/JCP.19m13207.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"1197_CR37","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S2215-0366(23)00005-6","volume":"10","author":"I Winter-van Rossum","year":"2023","unstructured":"Winter-van Rossum I, Weiser M, Galderisi S, Leucht S, Bitter I, Glenth\u00f8j B, et al. Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST). Lancet Psychiatry. 2023;10(3):197\u2013208. https:\/\/doi.org\/10.1016\/S2215-0366(23)00005-6.","journal-title":"Lancet Psychiatry"},{"issue":"1","key":"1197_CR38","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.euroneuro.2004.07.003","volume":"15","author":"P Chue","year":"2005","unstructured":"Chue P, Eerdekens M, Augustyns I, Lachaux B, Molcan P, Eriksson L, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol. 2005;15(1):111\u20137. https:\/\/doi.org\/10.1016\/j.euroneuro.2004.07.003.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"6","key":"1197_CR39","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1176\/appi.ajp.160.6.1125","volume":"160","author":"JM Kane","year":"2003","unstructured":"Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003;160(6):1125\u201332. https:\/\/doi.org\/10.1176\/appi.ajp.160.6.1125.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"1197_CR40","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/JCP.0000000000000479","volume":"36","author":"AF Nasser","year":"2016","unstructured":"Nasser AF, Henderson DC, Fava M, Fudala PJ, Twumasi-Ankrah P, Kouassi A, et al. Efficacy, safety, and tolerability of RBP-7000 once-monthly risperidone for the treatment of acute schizophrenia: an 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 study. J Clin Psychopharmacol. 2016;36(2):130\u201340. https:\/\/doi.org\/10.1097\/JCP.0000000000000479.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"1197_CR41","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/01.yic.0000133500.92025.20","volume":"19","author":"M Turner","year":"2004","unstructured":"Turner M, Eerdekens E, Jacko M, Eerdekens M. Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. Int Clin Psychopharmacol. 2004;19(4):241\u20139. https:\/\/doi.org\/10.1097\/01.yic.0000133500.92025.20.","journal-title":"Int Clin Psychopharmacol"},{"key":"1197_CR42","unstructured":"Risperdal Consta\u00ae (risperidone) long-acting injection [prescribing information]. Titusville: Janssen Pharmaceutical Companies; 2021."},{"key":"1197_CR43","unstructured":"Perseris\u2122 (risperidone) extended-release injectable suspension [prescribing information]. North Chesterfield: Indivior Inc; 2021."},{"key":"1197_CR44","unstructured":"Rykindo\u00ae (risperidone) extended-release injectable suspension [prescribing information]. Yantai: Shandong Luye Pharmaceutical Co., Ltd.; 2023."},{"issue":"12","key":"1197_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006918.pub3","volume":"12","author":"RD Rattehalli","year":"2016","unstructured":"Rattehalli RD, Zhao S, Li BG, Jayaram MB, Xia J, Sampson S. Risperidone versus placebo for schizophrenia. Cochrane Database Syst Rev. 2016;12(12): CD006918. https:\/\/doi.org\/10.1002\/14651858.CD006918.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"1197_CR46","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/cpdd.1078","volume":"11","author":"I Perlstein","year":"2022","unstructured":"Perlstein I, Merenlender Wagner A, Gomeni R, Lamson M, Harary E, Spiegelstein O, et al. Population pharmacokinetic modeling and simulation of TV-46000: a long-acting injectable formulation of risperidone. Clin Pharmacol Drug Dev. 2022;11(7):865\u201377. https:\/\/doi.org\/10.1002\/cpdd.1078.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"1197_CR47","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1471-244X-11-21","volume":"11","author":"I Turkoz","year":"2011","unstructured":"Turkoz I, Bossie CA, Lindenmayer JP, Schooler N, Canuso CM. Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis. BMC Psychiatry. 2011;11:21. https:\/\/doi.org\/10.1186\/1471-244X-11-21.","journal-title":"BMC Psychiatry"},{"issue":"3","key":"1197_CR48","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1093\/schbul\/sbac001","volume":"48","author":"H Wu","year":"2022","unstructured":"Wu H, Siafis S, Hamza T, Schneider-Thoma J, Davis JM, Salanti G, et al. Antipsychotic-induced weight gain: dose-response meta-analysis of randomized controlled trials. Schizophr Bull. 2022;48(3):643\u201354. https:\/\/doi.org\/10.1093\/schbul\/sbac001.","journal-title":"Schizophr Bull"},{"issue":"7","key":"1197_CR49","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1093\/ijnp\/pyad029","volume":"26","author":"CU Correll","year":"2023","unstructured":"Correll CU, H\u00f8jlund M, Graham C, Todtenkopf MS, McDonnell D, Simmons A. Weight gain and metabolic changes in patients with first-episode psychosis or early-phase schizophrenia treated with olanzapine: a meta-analysis. Int J Neuropsychopharmacol. 2023;26(7):451\u201364. https:\/\/doi.org\/10.1093\/ijnp\/pyad029.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"2","key":"1197_CR50","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/wps.20632","volume":"18","author":"T Kishimoto","year":"2019","unstructured":"Kishimoto T, Hagi K, Nitta M, Kane JM, Correll CU. Long-term effectiveness of oral second-generation antipsychotics in patients with schizophrenia and related disorders: a systematic review and meta-analysis of direct head-to-head comparisons. World Psychiatry. 2019;18(2):208\u201324. https:\/\/doi.org\/10.1002\/wps.20632.","journal-title":"World Psychiatry"},{"issue":"1","key":"1197_CR51","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","volume":"7","author":"T Pillinger","year":"2020","unstructured":"Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7(1):64\u201377. https:\/\/doi.org\/10.1016\/S2215-0366(19)30416-X.","journal-title":"Lancet Psychiatry"},{"issue":"12","key":"1197_CR52","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209\u201323. https:\/\/doi.org\/10.1056\/NEJMoa051688.","journal-title":"N Engl J Med"},{"issue":"6","key":"1197_CR53","first-page":"575","volume":"169","author":"O Serri","year":"2003","unstructured":"Serri O, Chik CL, Ur E, Ezzat S. Diagnosis and management of hyperprolactinemia. CMAJ. 2003;169(6):575\u201381.","journal-title":"CMAJ"},{"issue":"10","key":"1197_CR54","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S2215-0366(21)00241-8","volume":"8","author":"H Taipale","year":"2021","unstructured":"Taipale H, Solmi M, Lahteenvuo M, Tanskanen A, Correll CU, Tiihonen J. Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland. Lancet Psychiatry. 2021;8(10):883\u201391. https:\/\/doi.org\/10.1016\/S2215-0366(21)00241-8.","journal-title":"Lancet Psychiatry"},{"key":"1197_CR55","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbae058","author":"M Solmi","year":"2024","unstructured":"Solmi M, Lahteenvuo M, Tanskanen A, Corbeil O, Mittendorfer-Rutz E, Correll CU, et al. Antipsychotic use and risk of breast cancer in women with severe mental illness: replication of a nationwide nested case-control database study. Schizophr Bull. 2024. https:\/\/doi.org\/10.1093\/schbul\/sbae058.","journal-title":"Schizophr Bull"},{"issue":"5","key":"1197_CR56","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1097\/JCP.0000000000001076","volume":"39","author":"A Andorn","year":"2019","unstructured":"Andorn A, Graham J, Csernansky J, Newcomer JW, Shinde S, Muma G, et al. Monthly extended-release risperidone (RBP-7000) in the treatment of schizophrenia: results from the phase 3 program. J Clin Psychopharmacol. 2019;39(5):428\u201333. https:\/\/doi.org\/10.1097\/JCP.0000000000001076.","journal-title":"J Clin Psychopharmacol"},{"key":"1197_CR57","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.schres.2021.11.030","volume":"239","author":"Y Filts","year":"2022","unstructured":"Filts Y, Litman RE, Mart\u00ednez J, Anta L, Naber D, Correll CU. Long-term efficacy and safety of once-monthly Risperidone ISM\u00ae in the treatment of schizophrenia: results from a 12-month open-label extension study. Schizophr Res. 2022;239:83\u201391. https:\/\/doi.org\/10.1016\/j.schres.2021.11.030.","journal-title":"Schizophr Res"},{"issue":"1","key":"1197_CR58","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1017\/S1461145711001076","volume":"15","author":"WW Fleischhacker","year":"2012","unstructured":"Fleischhacker WW, Gopal S, Lane R, Gassmann-Mayer C, Lim P, Hough D, et al. A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. Int J Neuropsychopharmacol. 2012;15(1):107\u201318. https:\/\/doi.org\/10.1017\/S1461145711001076.","journal-title":"Int J Neuropsychopharmacol"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01197-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01197-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01197-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:04:26Z","timestamp":1760173466000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01197-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,29]]},"references-count":58,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1197"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01197-1","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,29]]},"assertion":[{"value":"26 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Teva Branded Pharmaceutical Products R&D LLC.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Sponsor"}},{"value":"This study was supported by Teva Branded Pharmaceutical Products R&D LLC.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"C.U. Correll has been a consultant and\/or advisor to or has received honoraria from AbbVie, Acadia, Adock Ingram, Alkermes, Allergan, Angelini, Aristo, Biogen, Boehringer-Ingelheim, Bristol-Meyers Squibb, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Delpor, Denovo, Eli Lilly, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Jamjoom Pharma, Janssen\/J&J, Karuna, LB Pharma, Lundbeck, MedInCell, Merck, Mindpax, Mitsubishi Tanabe Pharma, Maplight, Mylan, Neumora Therapeutics, Neurocrine, Neurelis, Newron, Noven, Novo Nordisk, Otsuka, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Sage, Saladax, Sanofi, Seqirus, SK Life Science, Sumitomo Pharma America, Sunovion, Sun Pharma, Supernus, Tabuk, Takeda, Teva, Tolmar, Vertex, Viatris, and Xenon Pharmaceuticals; provided expert testimony for Janssen, Lundbeck and Otsuka; served on a Data Safety Monitoring Board for Compass Pathways, Denovo, IntraCellular Therapies, Lundbeck, Relmada, Reviva, Rovi, Supernus, and Teva; received grant support from Boehringer-Ingelheim, Janssen, and Takeda; received royalties from UpToDate; and is a stock option holder of Cardio Diagnostics, Kuleon Biosciences, LB Pharma, Medlink, Mindpax, Quantic, and Terran. H. Knebel, E. Harary, R. Eshet, O. Tohami, N. Sharon, and K.R. Franzenburg are employees and shareholders of Teva Pharmaceuticals. M. Suett is an employee and stockholder of Teva UK. J.M. Kane has been a consultant for or received honoraria from Alkermes, Boehringer Ingelheim, Cerevel, Click Therapuetics, HLS Therapuetics, Intra-Cellular Therapies, Janssen, Johnson & Johnson, Karuna Therapeutics, LB Pharmaceuticals, Lundbeck, Lyndra Therapeutics, Merck, Neurocrine Biosciences, Newron, Otsuka, Pierre Fabre, Reviva Pharmaceuticals, Roche, Saladax Biomedical, Sunovion, Takeda, and Teva Pharmaceuticals; has received grant support from Otsuka, Lundbeck, and Janssen and is a shareholder or option holder of Health Rhythms, Intracellular Therapies, LB Pharmaceuticals, Medincell, NW PharmaTech, North Shore Therapies and Vanguard Research Group.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Qualified researchers may request access to patient-level data and related study documents, including the study protocol and statistical analysis plan. Requests will be reviewed for scientific merit, product approval status, and conflicts of interest. Patient-level data will be de-identified and study documents will be redacted to protect the privacy of trial participants and to protect commercially confidential information. Please email USMedInfo@tevapharm.com to make your request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing statement"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The protocol and subsequent amendments were approved before the start of the study by independent ethics committees (IECs)\/institutional review boards (IRBs) according to national or local regulations. IEC\/IRB organizations and approval numbers for the study include the following: Western IRB (20180568), Western IRB and WCG (ICO1-18-072), Copernicus Group (20190551), and Republic of Bulgaria\/Ethics Committee for Clinical Trials (KEMI\/CT-0412). This study was conducted in full accordance with the International Council for Harmonisation Good Clinical Practice Consolidated Guideline (E6) and any applicable national and local laws and regulations.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Participants provided informed consent or assent, as applicable, at screening, before any study-related procedures or assessments were performed.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"J.M.K., R.E., E.H., O.T., and N.S. conceived and designed the study. J.M.K., R.E., E.H., O.T., H.K., N.S., M.S., K.R.F., and C.U.C. acquired, analyzed, and interpreted the data. R.E., E.H., O.T., H.K., N.S., and C.U.C. verified the data. J.M.K., R.E., E.H., O.T., H.K., N.S., M.S., K.R.F., and C.U.C. accessed the data. J.M.K., R.E., E.H., O.T., H.K., N.S., M.S., K.R.F., and C.U.C. drafted the manuscript. J.M.K., R.E., E.H., O.T., H.K., N.S., M.S., K.R.F., and C.U.C. critically revised the manuscript for important intellectual content. N.S. did the statistical analysis. G.L.D. provided administrative, technical, or material support. J.M.K., R.E., E.H., O.T., H.K., N.S., M.S., K.R.F., and C.U.C. approved the final submitted version and agree to be accountable for the work.","order":10,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}